Valuation: Cerus Corporation

Market Cap 455M 407M 379M 344M 647M 43.23B 652M 4.54B 1.78B 22.48B 1.71B 1.67B 72.15B P/E 2026 *
-64.6x
P/E 2027 * -226x
Enterprise Value 460M 411M 383M 348M 654M 43.71B 659M 4.59B 1.8B 22.73B 1.73B 1.69B 72.94B EV / Sales 2026 *
1.85x
EV / Sales 2027 * 1.63x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 week-3.42%
Current month-5.04%
1 month-9.24%
3 months-26.86%
6 months+17.71%
Current year+9.71%
1 week 2.2
Extreme 2.2
2.33
1 month 2.2
Extreme 2.2
2.69
Current year 1.62
Extreme 1.62
3.47
1 year 1.38
Extreme 1.38
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 2026-06-30
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Director TitleAgeSince
Chairman 59 2026-03-15
Director/Board Member 72 2014-03-23
Director/Board Member 51 2026-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

General Counsel

-30,000 0.0150%
7/16/26 Sell

Chief Executive Officer

-16,666 0.0083%
7/1/26 Free

Chief Executive Officer

924,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.42%+44.87%+75.19% 455M
+0.78%+4.53%-21.90%+12.92% 176B
+1.17%+6.80%-2.69%+29.25% 118B
-0.02%+1.56%-22.57%+9.57% 108B
-0.31%-0.27%-46.72%-10.85% 75.34B
+1.55%+4.34%+4.14%+74.68% 62.03B
+1.24%+1.83%+20.67%+68.28% 52.8B
-0.80%+3.92%+0.38%-27.57% 51.45B
-0.69%+0.95%-17.84%+22.09% 41.28B
-1.00%+2.00%+30.46%+11.64% 32.42B
Average +0.18%+2.29%-1.12%+26.52% 71.8B
Weighted average by Cap. +0.42%+3.40%-11.84%+19.61%

Financials

2026 *2027 *
Net sales 249M 222M 207M 188M 354M 23.64B 357M 2.48B 972M 12.29B 935M 915M 39.45B 272M 243M 226M 205M 386M 25.77B 389M 2.71B 1.06B 13.4B 1.02B 997M 43.01B
Net income -8.77M -7.83M -7.3M -6.62M -12.45M -832M -12.55M -87.44M -34.23M -433M -32.92M -32.2M -1.39B -1.67M -1.49M -1.39M -1.26M -2.37M -158M -2.39M -16.62M -6.51M -82.28M -6.26M -6.12M -264M
Net Debt 5M 4.47M 4.16M 3.77M 7.1M 475M 7.16M 49.87M 19.52M 247M 18.78M 18.37M 792M -13M -11.61M -10.82M -9.81M -18.47M -1.23B -18.61M -130M -50.76M -642M -48.82M -47.75M -2.06B
Projected Income Statement - Annual - Cerus Corporation
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
26-10-13 $2.260 0.00% 2,293,132
26-10-12 $2.260 -1.74% 1,179,807
26-10-09 $2.300 +0.88% 787,967
26-10-08 $2.280 -0.44% 2,419,512
26-10-07 $2.290 -2.14% 888,398
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Cerus Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.260USD
Average target price
5.125USD
Spread / Average Target
+126.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cerus Corporation
  1. Stock Market
  2. Stocks
  3. CERS Stock